Luca Stirparo

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances
Published: October 22, 2025

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Journal: Blood advances
Published: June 13, 2025

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Journal: Blood advances
Published: March 18, 2025

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Journal: Hematological oncology
Published: December 02, 2024

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Journal: Hematological oncology
Published: November 15, 2024

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Journal: HemaSphere
Published: May 28, 2024

Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature.

Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature.

Journal: Therapeutic advances in hematology
Published: May 27, 2024

First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.

First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.

Journal: American journal of hematology
Published: May 03, 2024

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.

Journal: Cancers
Published: April 16, 2024

Role of microRNAs in Chronic Lymphocytic Leukemia.

Role of microRNAs in Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences
Published: July 05, 2023

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study.

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study.

Journal: Haematologica
Published: October 14, 2022

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.

Journal: Frontiers in oncology
Published: March 16, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026